Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

For more than a decade, Michelle Hobson endured extreme fatigue, excruciating abdominal pain, and repeated hospital visits.

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Jefferies lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $42 from $53 and keeps a Buy rating on the shares. For the FY24 ...